

# STRENGTHENING COUNTRY TRANSITIONS OUT OF GAVI SUPPORT

---


BOARD MEETING  
Judith Kallenberg, Santiago  
Cornejo, Aurelia Nguyen

10-11 June 2015, Geneva



Reach every child  
[www.gavi.org](http://www.gavi.org)

# Policy review process




## Analyses:

- Economic growth projections, graduation dates
- Cost to countries, cost to Gavi
- Fiscal space analyses
- Health impact and risks
- Options/scenario modelling

## Consultations:


- Health / development economists
- Technical Consultation Group
- Constituencies
- Countries
- Public (web) consultation

# By 2020, 32 countries will have graduated or will be in the process of graduating




\*Projections (may change when new estimates released in July 2015)

# Review of terminology



# Earlier preparations for the end of Gavi support, from the start of the transition




## Increase consideration of financial sustainability and build familiarity with the vaccine markets early on

- Link co-financing to vaccine prices starting from Phase 1
- Improved communication and information sharing to inform holistic decision-making on new vaccine introduction

## Intensify support through Partner Engagement Framework

- Earlier transition assessments
- Advocacy to increase political will for immunisation

# Successful Phase 2 requires predictability and planning



**Average GNI per capita of past 3 years determines change in status from ‘Phase 1’ (eligible) to ‘Phase 2’ (graduating)**

- Create greater predictability

**Extend Phase 1 for countries that enter Phase 2 earlier than expected due to rapid GNI growth**

- Ensure preparedness for Phase 2 for countries on an accelerated trajectory out of Gavi support
- Mitigate risks to successful transition

# Offer catalytic support for 'late arrival' vaccines

## **One-off, catalytic support for introduction of HPV, MR, JE vaccines in sub-set of graduating countries**

- Phase 2 countries from 2011 cohort missed opening of 'support window' for HPV, MR, JE
- Offer limited support to catalyse introductions (50% of doses + Vaccine Introduction Grant)

# Financial implications

---

<b>Proposals</b>	<b>Cost (US\$ millions) 2016-2020</b>
<b>Transition &amp; Eligibility Policy</b>	
- Eligibility indicator: 3-year average GNI p.c.	\$21M
- Extended Phase 1 for countries meeting criteria	\$173-189M
<b>Catalytic support for 'late arrival' vaccines</b>	\$5M
<b>Implementation cost (through Partner Engagement Framework)</b>	\$15M
<b>Total</b>	<b>\$214-230M</b>

---

# Risks and mitigation

Potential risks	Mitigation
<b>Weakened incentives</b> Extension of Phase 1 may discourage domestic investment in immunisation	<ul style="list-style-type: none"><li>▪ 5-year graduation period maintained with rapid increase in domestic investment</li><li>▪ Suspension of Gavi support in case of default</li></ul>
<b>‘Scope creep’ or ‘gaming’</b> Other countries may seek flexibilities or policy may be ‘gamed’ for benefits	<ul style="list-style-type: none"><li>▪ Extension of Phase 1 only if objective criteria are met</li><li>▪ GNI p.c. criterion precludes gaming</li></ul>
<b>Incomplete solution</b> Countries fail to make a successful transition despite policy changes	<ul style="list-style-type: none"><li>▪ Some uncertainty and risk remains</li><li>▪ Close monitoring of progress</li></ul>

# Recommendations

---

The Gavi Programme and Policy Committee:

**Recommended** to the Gavi Board that it:

- (a) **Approve** the Eligibility & Transition Policy attached as Annex A to Doc 05
- (b) **Note** the importance of enhancing Gavi's approach to supporting country transitions and **request** the Secretariat and Alliance Partners to scale up their engagement with countries as they (prepare for the) transition to full self-financing as described in section 11.3 of Doc 04 of the 4-6 May PPC meeting.
- (c) **Approve** providing a time-limited opportunity to access exceptional catalytic support for the introduction of HPV, MR and/or JE vaccines for those Phase 2 countries that did not have the possibility to apply for these vaccines, due to the timing of the vaccines' availability.

**THANK YOU**

---



Reach every child  
[www.gavi.org](http://www.gavi.org)